FDA accepts tinlarebant NDA with priority review, target action date Feb. 12, 2027
AI Summary- FDA accepted Belite Bio’s tinlarebant application for priority review.
- February 12, 2027, is the PDUFA target action date for FDA’s decision.
- Belite Bio submitted a parallel tinlarebant application to Japan’s MHLW under Sakigake designation.